# ACCURAY INC (ARAY) — tender_offer/third_party [pending]
Source: sec.gov · situation sit_244ed6aa57a32b067a71 · public 8909788448998639000 · retrieved 2026-09-03T11:41:36.346Z

## Overview
Accuray Inc. manufactures and sells radiation therapy and radiosurgery systems for cancer treatment.

On July 29, 2026, Accuray Incorporated entered into a Securities Purchase Agreement with certain existing investors, including affiliates of TCW Group Inc., to issue and sell 55,000 shares of Series A Convertible Preferred Stock at $1,000 per share for an aggregate purchase price of $55.0 million. The consideration consists of $15.0 million in cash paid at signing and $40.0 million in conversion of existing indebtedness held by the Investors under the Financing Agreement, with such indebtedness to be cancelled and extinguished. The Series A Preferred Stock is initially convertible into Common Stock at a conversion price of $0.50 per share (2,000 shares per $1,000 of stated value). In connection with the transaction, Accuray issued warrants to TCW Rescue Financing Fund II, L.P. (7,987,743 shares) and TCW WV Financing LLC (598,114 shares), each with an exercise price of $0.01 per share and a 7-year term expiring July 29, 2033. The closing of the Issuance is subject to certain conditions, including stockholder approval.

## Terms
- Counterparty: TCW Group Inc. (on behalf of TCW Business Unit, including TCW Rescue Financing Fund II, L.P. and TCW WV Financing LLC) · Deal value: $55.0M · Consideration: mixed · Stake: 18.7% · Price/share: $1000

## Key dates
- Announced 2026-09-03

## Timeline
- 2026-09-03 · SCHEDULE 13D/A (0001104659-26-104846): SCHEDULE 13D/A - ACCURAY INC — *Accuray Inc. manufactures and sells radiation therapy and radiosurgery systems for cancer treatment.* On July 29, 2026, Accuray Incorporated entered into a Securities Purchase Agreement with certain existing investors, including affiliates of TCW Group Inc., to issue and sell 55,000 shares of Series A Convertible Preferred Stock at $1,000 per share for an aggregate purchase price of $55.0 million. The consideration consists of $15.0 million in cash paid at signing and $40.0 million in conversion of existing indebtedness held by the Investors under the Financing Agreement, with such indebtedness to be cancelled and extinguished. The Series A Preferred Stock is initially convertible into Common Stock at a conversion price of $0.50 per share (2,000 shares per $1,000 of stated value). In connection with the transaction, Accuray issued warrants to TCW Rescue Financing Fund II, L.P. (7,987,743 shares) and TCW WV Financing LLC (598,114 shares), each with an exercise price of $0.01 per share and a 7-year term expiring July 29, 2033. The closing of the Issuance is subject to certain conditions, including stockholder approval.
  https://www.sec.gov/Archives/edgar/data/1138723/0001104659-26-104846.txt

## Citations
- 0001104659-26-104846 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926104846